Noah Voreades BA

Noah has been personally and professionally involved in the microbiome, genomic and personalized health space for the past five years. Recently, leading strategic, product development, regulatory and R&D engagements with Fortune 100 to emerging growth start-ups. In the microbiome space, projects have ranged from advising Fortune-level biotechs on microbiome investment/pipeline/industry trends in support of recent acquisitions, developing R&D strategy for emerging a microbiome CPG beverage to collaborating with one of the leading global probiotic brands on disease indication expansion options. Genomic and personalized health sector engagements have focused on industry intelligence, sales channel positioning, product development and scientific due diligence for DTC genetic or microbiome-based tests with clients ranging from Fortune 100 to venture-backed start-ups. Previously, Noah was Business Development Manager at Ritter Pharmaceuticals, a late-stage microbiome Rx/GI company developing potentially the first FDA approved treatment for moderate-to-severe lactose intolerance. Noah’s microbiome expertise reaches beyond therapeutics and nutraceuticals to diagnostics and sample collection technology in a business development role with Metabiomics. Metabiomics is an early-stage microbiome Dx company with multiple patents in IBD and CRC diagnostic development.